Outpatient intensive chemotherapy for Small Cell Lung Cancer: Five years experience of modified 'ICE' ifosfamide carboplatin and etoposide

Clinical Oncology

Volumn 14, Issue 5, 2002, Pages 367-371

  Hand, S ^a   Baker, J ^a   Smith, A P ^a   Macbeth, F R ^b  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b VELINDRE CANCER CENTRE   (United Kingdom)

Author keywords

'ICE' chemotherapy; Modified regimen; Small cell lung cancer

Indexed keywords

CARBOPLATIN; CIPROFLOXACIN; DEXAMETHASONE; ETOPOSIDE; IFOSFAMIDE; MESNA; ONDANSETRON;

ADULT; AGED; ALOPECIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEUTROPENIA; OUTPATIENT CARE; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; WORLD HEALTH ORGANIZATION;

EID: 0036786077     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.2002.0097     Document Type: Article

References (17)

1. Elias AD. Small cell lung cancer: state-of-the-art. Chest 1997; 112(4 suppl):251S-258S.
2. Royal College of Radiologists' Clinical Oncology Information Network Guidelines on the non-surgical management of lung cancer. Clin Oncol 1999;11:S1-S53.
3. Report to the Medical Research Council by its lung cancer working party. Survival, adverse reactions and quality of life during combination chemotherapy compared with selective palliative treatment for small-cell lung cancer. Resp Med 1989;83:51-58.
4. Ihde DC, Pass HI, Gladstein EJ. Small cell lung cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology, 5th edn. Philadelphia: JB Lippincott 1997.
5. Report of a Working Group to the Standing Medical Advisory Committee, Department of Health (1994). Management of Lung Cancer. Current clinical practices.
6. The Royal College of Radiologists Clinical Oncology Information Network (COIN). Clin Oncol 1999;11:S1-S53.
7. Scottish Intercollegiate Guidelines Network (SIGN). Pilot edition, February 1998.
8. Kamthan AG, Lind MJ, Thatcher N, et al. Ifosfamide, Doxorubicin and Etoposide in small cell lung cancer patients with poor prognosis. Eur J Cancer 1990;26(6):691-694.
9. Steward WP, von Pawel J, Gatzemeier U, et al. Effects of granulocyte-macrophage colony stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol 1998;16:642-650.
10. Prendiville J, Radford J, Thatcher N, et al. Intensive therapy for small-cell lung cancer using carboplatin alternating with Cisplatin, Ifosfamide, Etoposide, cide-cycle Vincristine, and Radiotherapy. J Clin Oncol 1991;9:1446-1452.
11. Prendiville J, Lorigan P, Hicks F, et al. Therapy for small cell lung cancer using Carboplatin, Ifosfamide, Etoposide (without dose reduction), mid-cycle Vincristine with thoracic and cranial irradiation. Eur J Cancer 1994;30A(14:2085-2095.
12. Thatcher N. Ifosfamide/Carboplatin/Etoposide (ICE) regimen in small cell lung cancer. Lung Cancer 1993;9(suppl 1):S51-S67.
13. Shevlin PM, Muers MF, Peak MD, et al. Modified ice study: A phase II study of an intensive, modified ICE regimen (ifosfamide, carboplatin and etoposide) in patients with small cell lung cancer. Lung Cancer 1998;21:115-126.
14. Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer 1987;39:146-149.
15. Cockcroft DW, Gault MH. Prediction of Creatinine clearance from serum Creatinine. Nephron 16:31-41.
16. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214.
17. Howell ST, Bhaskaran R, Middleton MR, Thatcher N. Dose intensification of chemotherapy in small cell lung cancer. In: Muers M, Macbeth F, Wells F, Miles A, eds. The Effective Management of Lung Cancer. Aesculapius Medical Press 2001; 93-104.